Date | Time | Source | Headline | Symbol | Company |
09/09/2024 | 1:34PM | iHub Newswire | FeaturedElement79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. | | |
08/02/2013 | 11:03AM | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NYSE:FRX | Forest Road Acquisition Corp |
07/30/2013 | 7:00AM | PR Newswire (US) | Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study | NYSE:FRX | Forest Road Acquisition Corp |
07/30/2013 | 3:10AM | Zacks | Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook | NYSE:FRX | Forest Road Acquisition Corp |
07/30/2013 | 3:10AM | Zacks | Pharma & Biotech Stock Outlook - July/Aug 2013 - Zacks Analyst Interviews | NYSE:FRX | Forest Road Acquisition Corp |
07/29/2013 | 8:00AM | PR Newswire (US) | Seeking Growth Opportunities through Understanding Market Trends, Strengthened R&D, and Global Expansion - Research Report on... | NYSE:FRX | Forest Road Acquisition Corp |
07/26/2013 | 4:15PM | Business Wire | ADDINGÂ MULTIMEDIA:Â Forest Laboratories & Pierre Fabre Laboratories Announce FDA Approval of FETZIMAâ„¢ for the Treatment of... | NYSE:FRX | Forest Road Acquisition Corp |
07/26/2013 | 4:15PM | Business Wire | ADDINGÂ MULTIMEDIA:Â Forest Laboratories & Pierre Fabre Laboratories Announce FDA Approval of FETZIMAâ„¢ for the Treatment of... | NYSE:FRX | Forest Road Acquisition Corp |
07/26/2013 | 2:00AM | Business Wire | Forest Laboratories & Pierre Fabre Laboratories Announce FDA Approval of FETZIMAâ„¢ for the Treatment of Major Depressive Dis... | NYSE:FRX | Forest Road Acquisition Corp |
07/26/2013 | 2:00AM | Business Wire | Forest Laboratories & Pierre Fabre Laboratories Announce FDA Approval of FETZIMAâ„¢ for the Treatment of Major Depressive Dis... | NYSE:FRX | Forest Road Acquisition Corp |
07/23/2013 | 9:52AM | Edgar (US Regulatory) | Mutual Fund Summary Prospectus (497k) | NYSE:FRX | Forest Road Acquisition Corp |
07/23/2013 | 9:52AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NYSE:FRX | Forest Road Acquisition Corp |
07/23/2013 | 7:00AM | Business Wire | Forest Laboratories, Inc. Reports Fiscal Year First Quarter 2014 Diluted Earnings Per Share of $0.09 Including Effect of $0.0... | NYSE:FRX | Forest Road Acquisition Corp |
07/23/2013 | 7:00AM | Business Wire | Forest Laboratories, Inc. Reports Fiscal Year First Quarter 2014 Diluted Earnings Per Share of $0.09 Including Effect of $0.0... | NYSE:FRX | Forest Road Acquisition Corp |
07/22/2013 | 12:10PM | Edgar (US Regulatory) | Post-effective Amendment (investment Company, Rule 485(b)) (485bpos) | NYSE:FRX | Forest Road Acquisition Corp |
07/22/2013 | 12:09PM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NYSE:FRX | Forest Road Acquisition Corp |
07/22/2013 | 8:00AM | Business Wire | Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC® Patent Litigation | NYSE:FRX | Forest Road Acquisition Corp |
07/22/2013 | 8:00AM | Business Wire | Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC® Patent Litigation | NYSE:FRX | Forest Road Acquisition Corp |
07/17/2013 | 7:00AM | PR Newswire (US) | Trevena Granted Key Composition of Matter Patent for TRV027 in U.S. | NYSE:FRX | Forest Road Acquisition Corp |
07/08/2013 | 5:20PM | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NYSE:FRX | Forest Road Acquisition Corp |
07/01/2013 | 8:53AM | Business Wire | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 First Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
07/01/2013 | 8:53AM | Business Wire | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 First Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
06/27/2013 | 8:00AM | Business Wire | Forest Laboratories Announces Positive Phase III Study Results for Nebivolol and Valsartan Combination in Hypertension | NYSE:FRX | Forest Road Acquisition Corp |
06/27/2013 | 8:00AM | Business Wire | Forest Laboratories Announces Positive Phase III Study Results for Nebivolol and Valsartan Combination in Hypertension | NYSE:FRX | Forest Road Acquisition Corp |
06/20/2013 | 3:16PM | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NYSE:FRX | Forest Road Acquisition Corp |
06/13/2013 | 1:23PM | Edgar (US Regulatory) | Amended Annual Report (10-k/a) | NYSE:FRX | Forest Road Acquisition Corp |
06/13/2013 | 8:00AM | Business Wire | Forest Announces U.S. Availability of New Once-Daily NAMENDA XR | NYSE:FRX | Forest Road Acquisition Corp |
06/13/2013 | 8:00AM | Business Wire | Forest Announces U.S. Availability of New Once-Daily NAMENDA XR | NYSE:FRX | Forest Road Acquisition Corp |
06/11/2013 | 5:01PM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NYSE:FRX | Forest Road Acquisition Corp |
06/11/2013 | 4:12PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:FRX | Forest Road Acquisition Corp |